Antiarrhythmic Drugs Market Assessment, By Drug Class [Sodium Channel Blockers, Beta Blockers, Potassium Channel Blockers, Calcium Channel Blockers, Others], By Route of Administration [Oral, Parenteral, Others], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Others], By Region, Opportunities and Forecast, 2018-2032F

Market Report | 2025-06-16 | 225 pages | Market Xcel - Markets and Data

AVAILABLE LICENSES:

- Single User License $4800.00
- Muti-User/Corporate Licence $6000.00
- Custom Research License $8500.00

Report description:

Global antiarrhythmic drugs market is projected to witness a CAGR of 6.22% during the forecast period 2025-2032, growing from USD 1.15 billion in 2024 to USD 1.86 billion in 2032. The market's growth can be attributed to increasing cardiovascular diseases across the globe, rising awareness about cardiac conditions among the general population, and growing focus of pharmaceutical companies on manufacture antiarrhythmic drugs. The World Health Organization (WHO) estimates that cardiovascular diseases are responsible for approximately 17.9 million deaths every year.

The increasing burden of lifestyle-related disorders, including obesity, hypertension, and diabetes, contributes to the growing demand for antiarrhythmic medications. However, some drugs in this class carry a high risk of adverse effects, including proarrhythmia and organ toxicity, which may limit their utilization. Additionally, the expansion of the global aging population and technological advancements in cardiac care are expected to boost the adoption of these drugs in the coming years.

Increasing Prevalence of Cardiovascular Diseases Boosts Market Demand

Rising cases of cardiovascular diseases are influencing the market's growth, with arrhythmias such as atrial fibrillation (AF) being one of the most common types of cardiac conditions. Atrial fibrillation is one of the most common arrhythmias that causes and contributes greatly to incidences of stroke across the globe. Expansion of the aging population and poor lifestyle choices are further anticipated to increase the incidence of AF and other arrhythmias. Thus, healthcare providers are emphasizing early screening, diagnosis, and management of arrhythmia among the patient population.

Advanced diagnostic tools such as wearable ECG monitors and AI-based platforms for rhythm detection are also creating a

streamlined, faster, and precise identification of arrhythmia, aiding in initiating treatment protocols that include antiarrhythmic medications in a time-efficient manner. Thus, leading medical device manufacturers focus on developing various arrhythmia monitoring devices. For instance, in January 2025, Medtronic plc announced results from their DEFINE AFib clinical study, demonstrating that Medtronic's LINQ family of insertable cardiac monitors (ICMs), including Reveal LINQ and LINQ II, utilize AI-based algorithms to predict risk thresholds for patients with AF accurately and were able to detect AF episodes and stratify patients into high-risk categories. Such technological integration in patient care increases the accuracy of decision-making, thereby positively impacting the demand for antiarrhythmic medications.

Growth of the Aging Population Supports Market Expansion

The growth of the aging population is a major driver for the expansion of the antiarrhythmic drugs market, as the older population is at a higher risk of developing cardiovascular diseases, including arrhythmias. The World Health Organization estimates that one in six people across the globe will be 60 or older by 2030. The growing elderly population leads to greater demand for effective antiarrhythmic therapies, as these therapeutic solutions are essential for controlling abnormal heart rhythms and reducing the risk of complications such as stroke and heart failure. Additionally, the increased healthcare expenditure, improved access to medical care, and heightened awareness about cardiovascular health among the elderly are further supporting the market's growth.

Retail Pharmacies Account for Significant Share of the Market

The retail pharmacy segment accounts for a major share of the global antiarrhythmic drugs market due to convenience and established patient trust in these institutions. Antiarrhythmic drugs are often prescribed for prolonged treatment in conditions such as atrial fibrillation and ventricular tachycardia; continuous and easy access to these drugs is very important for compliance and, consequently, good management of the diseases. Retail pharmacies provide patients with easy access to fill prescriptions time-efficiently, receive consultative advice from the pharmacist, and obtain refills without the need for hospital visits, further increasing their popularity, especially among the elderly who might be facing mobility issues.

Meanwhile, online pharmacies across the globe are working on increasing the availability of same-day delivery services. In October 2024, Amazon Pharmacy, a division of Amazon.com, Inc., unveiled plans to expand its same-day medication delivery service, doubling the number of cities covered. Leveraging cutting-edge automation and an extensive logistics network, the company seeks to address key challenges in the pharmacy industry, including improving affordability and enhancing convenience for patients.

North America Holds Major Market Share

The market's dominance in the region can be attributed to advanced healthcare infrastructure, high healthcare spending, widespread availability of cardiac diagnostic tools, and the presence of leading pharmaceutical manufacturers. The high prevalence of atrial fibrillation and ventricular arrhythmias, especially among the elderly population, are further driving the utilization of antiarrhythmic drugs. According to the estimates of the Centers for Disease Control and Prevention, approximately 12.1 million people in the United States have atrial fibrillation. This growing burden underscores the critical need for effective pharmacological interventions. Moreover, a large number of clinical trials and Food and Drug Administration (FDA) approvals for cardiovascular drugs originate in the United States, ensuring early market access to novel therapeutic solutions.

As digital health technology integrates more deeply into cardiovascular care, arrhythmia management is expected to become more efficient and tailored, creating new opportunities for drug developers based in the region. The emergence of minimally invasive interventions and hybrid therapy models that combine pharmacological and non-pharmacological approaches could also reshape treatment paradigms, providing lucrative growth opportunities for the market in North America.

Impact of the U.S. Tariff on Global Antiarrhythmic Drugs Market

The recent imposition of tariffs is expected to significantly impact the market and affect the affordability and availability of generic medications. The tariffs are also expected to disrupt pharmaceutical supply chains, especially for generics that usually rely on low-cost active pharmaceutical ingredients. The introduction of tariffs on pharmaceutical imports could also result in delays in sourcing critical drugs and increased costs, resulting in a shortage of essential drugs, including cardiovascular medicines. Pharmaceutical companies may explore alternative sourcing strategies, strengthening partnerships with suppliers across various regions. Additionally, a new dialogue between the policymakers and industry stakeholders will be crucial in navigating the trade complexities associated with the tariffs and ensuring public access to essential medications.

Key Players Landscape and Outlook

The key players in the market are collaborating with leading educational institutions to support the advancement of diagnostic techniques and treatment solutions for cardiac conditions. For instance, the American College of Cardiology (ACC) and Pfizer Inc. are collaborating to provide new grant opportunities for enhancing the identification and diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) among heart failure patients, the RFP date for which was April 2, 2025. Pfizer will provide funding, while ACC will oversee the selection of an Expert Review Panel (ERP) and create a community of practice for grantees. This initiative aligns with Pfizer's broader Global Medical Grants & Partnerships (GMGP) strategy, which supports independent healthcare projects to improve patient outcomes in areas where the medical requirements of the patient population are still unmet.

Table of Contents:

6.2.Market Share Analysis & Forecast
6.2.1.By Drug Class
6.2.1.1.Sodium Channel Blockers
6.2.1.2.Beta Blockers
6.2.1.3.Potassium Channel Blockers
6.2.1.4.Calcium Channel Blockers
6.2.1.5.Others
6.2.2.By Route of Administration
6.2.2.1.Oral
6.2.2.2.Parenteral
6.2.2.3.Others
6.2.3.By Distribution Channel
6.2.3.1.Hospital Pharmacies
6.2.3.2.Retail Pharmacies
6.2.3.3.Others
6.2.4.By Country Share
6.2.4.1.United States
6.2.4.2.Canada
6.2.4.3.Mexico
6.3.Country Market Assessment
6.3.1.United States Antiarrhythmic Drugs Market Outlook, 2018-2032F*
6.3.1.1.Market Size Analysis & Forecast
6.3.1.1.1.By Value
6.3.1.1.1.1.Market Share Analysis & Forecast
6.3.1.1.2.By Drug Class
6.3.1.1.2.1.Sodium Channel Blockers
6.3.1.1.2.2.Beta Blockers
6.3.1.1.2.3.Potassium Channel Blockers
6.3.1.1.2.4.Calcium Channel Blockers
6.3.1.1.2.5.Others
6.3.1.1.3.By Route of Administration
6.3.1.1.3.1.Oral
6.3.1.1.3.2.Parenteral
6.3.1.1.3.3.Others
6.3.1.1.4.By Distribution Channel
6.3.1.1.4.1.Hospital Pharmacies
6.3.1.1.4.2.Retail Pharmacies
6.3.1.1.4.3.Others
6.3.2.Canada
6.3.3.Mexico
*All segments will be provided for all regions and countries covered
7.Europe Antiarrhythmic Drugs Market Outlook, 2018-2032F
7.1.Germany
7.2.France
7.3.Italy
7.4.United Kingdom
7.5.Russia

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

Antiarrhythmic Drugs Market Assessment, By Drug Class [Sodium Channel Blockers, Beta Blockers, Potassium Channel Blockers, Calcium Channel Blockers, Others], By Route of Administration [Oral, Parenteral, Others], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Others], By Region, Opportunities and Forecast, 2018-2032F

Market Report | 2025-06-16 | 225 pages | Market Xcel - Markets and Data

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$4800.00
	Muti-User/Corporate Licence	$6000.00
	Custom Research License	$8500.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	

Address*		City*	
Zip Code*		Country*	
		Date	2025-06-25
		Signature	